A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

Tuberculosis Clinical Trial

— CL-004  

Official title:

A Phase 1, Open-Label, Single-Dose Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of [14C]-PA 824 in Healthy Adult Male Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03202693
• Other study ID #: PA 824-CL-004
• Status: Completed
• Phase: Phase 1
• Start date: March 2006
• Est. completion date: May 2006

Study information

• Verified date: February 2018
• Source: Global Alliance for TB Drug Development
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a Phase 1, single-center, open-label, single-dose study to evaluate (1) the absorption, metabolism, and excretion patterns of a single dose of [14C] PA-824, and (2) the pharmacokinetics, safety, and tolerability of a single oral-suspension dose of unlabeled PA-824 in healthy adult male subjects. Unlabeled PA-824 and [14C]-PA-824 will be administered together in an oral-suspension formulation. Enrollment is planned for one dose group of 6 subjects. All 6 subjects will receive the same treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: May 2006
• Est. primary completion date: May 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 19 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Be healthy non-tobacco/nicotine using (6-month minimum) adult male subjects, 19 to 50 years of age, inclusive

2. Weigh within 20% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Life Insurance Company, 1999)

3. Be medically healthy subjects with clinically insignificant Screening results (among laboratory profiles, medical histories, ECGs, or physical exam), as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor.

4. Have a history of regular bowel movements (5-6 movements week, ideally 1 per day), as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor.

5. Have negative urinalysis test results for drugs of abuse such as amphetamines, cannabinoids, and cocaine metabolites

6. Have the ability to understand the requirements of the study, have provided written informed consent (as evidenced by signature on an informed consent document approved by an IRB), and agree to abide by the study restrictions

Exclusion Criteria:

1. Any acute illness or history or presence of significant (as deemed by the Principal Investigator) cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease

2. Any preexisting condition that would interfere with normal anatomy or function of the gastrointestinal tract.

3. Any medical condition that would interfere with radiocarbon assessments.

4. Any serum creatinine or BUN measure beyond the upper limit of the normal range at Screening or Check-in.

5. Positive Screening test for HCV, HBV, or HIV

6. History of peptic ulcer disease, gastritis, esophagitis, or gastroesophageal reflux disease

7. History of any cardiac abnormality (as deemed by the Principal Investigator)

8. History of hypokalemia or hypomagnesemia

9. History of prolonged QT interval

10. Family history of Long-QT Syndrome or sudden death

11. Resting pulse rate < 40 or > 100 bpm at both Screening and Check-in

12. QTc interval > 430 msec as documented at Screening and Baseline (Check-in) ECG

13. History or presence of alcoholism or drug abuse within the past year (as deemed by the Principal Investigator)

14. Use of alcohol within 72 hours prior to dosing

15. Significant history of drug and/or food allergies (as deemed by the Principal Investigator)

16. Use of any prescription medication within 14 days prior to dosing or during the study

17. Use of any over-the-counter medication including vitamins, herbal preparations, antacids, cough and cold remedies, etc., within 7 days prior to dosing or during the study

18. Use of any drugs or substances within 30 days prior to dosing known to be strong inhibitors or inducers of cytochrome P450 enzymes or known to prolong the QT interval

19. Consumption of products containing grapefruit within 10 days prior to dosing

20. Any special dietary changes during the 30 days prior to dosing, as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor

21. Any strenuous exercise within 1 week of Check-in, as deemed by the Principal Investigator in consultation with the Sponsor Medical Monitor

22. Known allergies to Na CMC or DMSO, components of the formulation to be used in this study

23. Current employment in a job requiring radiation-exposure monitoring

24. Participation in any study involving radioactivity within the last 12 months

25. More than one X-ray greater than the equivalent of one routine chest X-ray or one routine dental X-ray in the past 12 months

26. Donation of whole blood within 56 days prior to dosing

27. Plasma donation within 7 days prior to dosing

28. Participation in another clinical trial within 30 days prior to dosing

29. Hemoglobin < 12.0 g/dL

30. Previous use of PA-824

Related Conditions & MeSH terms

• Tuberculosis

Intervention

Drug:
• PA-824

Locations

Country	Name	City	State
United States	Covance Clinical Research Unit	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
Global Alliance for TB Drug Development

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Characterize the plasma pharmacokinetic variable area under the curve of a single oral-suspension dose of PA-824.	Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable area under the curve [AUC (0-t)] from total PA-824 plasma concentrations.	Days 0-12
Primary	Characterize the plasma pharmacokinetic variable maximum concentration of a single oral-suspension dose of PA-824.	Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable maximum plasma concentration (Cmax) from total PA-824 plasma concentrations.	Days 0-12
Primary	Characterize the plasma pharmacokinetic variable time to peak plasma concentration of a single oral-suspension dose of PA-824.	Characterize the plasma pharmacokinetics of a single oral-suspension dose of PA-824 in healthy adult male subjects by calculating the variable time to peak plasma concentration (Tmax) from total PA-824 plasma concentrations.	Days 0-12
Secondary	The frequency and severity of treatment related adverse events throughout the study.	In order to evaluate the safety and tolerability of a single oral-suspension dose of PA-824 in healthy adult male subjects	Days 0 -12